Acasti Pharma Inc. (ACST)
Total Valuation
Acasti Pharma has a market cap or net worth of $27.16 million. The enterprise value is $6.82 million.
| Market Cap | 27.16M |
| Enterprise Value | 6.82M |
Important Dates
The next estimated earnings date is Tuesday, February 13, 2024, before market open.
| Earnings Date | Feb 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Acasti Pharma has 9.40 million shares outstanding.
| Shares Outstanding | 9.40M |
| Owned by Insiders (%) | 16.02% |
| Owned by Institutions (%) | 5.51% |
| Float | 6.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.68, with a Debt / Equity ratio of 0.00.
| Current Ratio | 20.68 |
| Quick Ratio | 19.93 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.50% and return on invested capital (ROIC) is -73.16%.
| Return on Equity (ROE) | -54.50% |
| Return on Assets (ROA) | -46.40% |
| Return on Capital (ROIC) | -73.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -7.46M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.50% in the last 52 weeks. The beta is 1.28, so Acasti Pharma's price volatility has been higher than the market average.
| Beta (1Y) | 1.28 |
| 52-Week Price Change | -6.50% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 2.58 |
| Relative Strength Index (RSI) | 70.86 |
| Average Volume (30 Days) | 21,500 |
Short Selling Information
| Short Interest | 59,686 |
| Short Previous Month | 76,752 |
| Short % of Shares Out | 0.70% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.88M |
| Pretax Income | -37.85M |
| Net Income | -40.27M |
| EBITDA | -37.83M |
| EBIT | -37.85M |
| Earnings Per Share (EPS) | -$4.08 |
Balance Sheet
The company has $20.38 million in cash and $34,717 in debt, giving a net cash position of $20.35 million or $2.16 per share.
| Cash & Cash Equivalents | 20.38M |
| Total Debt | 34,717 |
| Net Cash | 20.35M |
| Net Cash Per Share | $2.16 |
| Equity / Book Value | 50.37M |
| Book Value Per Share | 5.36 |
| Working Capital | 20.75M |
Cash Flow
In the last 12 months, operating cash flow was -$11.62 million and capital expenditures $76,981, giving a free cash flow of -$11.55 million.
| Operating Cash Flow | -11.62M |
| Capital Expenditures | 76,981 |
| Free Cash Flow | -11.55M |
| FCF Per Share | -$1.53 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Acasti Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -148.25% |
| FCF Yield | -42.51% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.72% |
| Shareholder Yield | -1.72% |
Analyst Forecast
The average price target for Acasti Pharma is $15.00, which is 419.03% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 419.03% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 10, 2023. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jul 10, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |